GEHC GE HealthCare Technologies Inc. Insider Trading

Director Kevin Lobo purchases 10,000 shares of GEHC at $64.18; stock down 28.5% from 52-week high of $89.77

Kevin Lobo, a Director at GE HealthCare Technologies Inc., purchased 10,000 shares at $64.18 on 2026-05-22, increasing his holdings from 4,363 shares to 14,363 shares (+229.2% net change). The transaction occurred at a price 28.5% below the 52-week high of $89.77, within a 52-week range of $58.75–$89.77, and follows a 23.6% decline over the prior 90 days. The company's fundamentals remain solid with $5.1B in quarterly revenue, $389.0M net income, and a P/E of 15.28. However, Lobo's cross-ticker track record shows a 0.00% well-timed rate on 7 prior open-market sells (average 90d return +8.2%), indicating his historical sales have not preceded declines. The purchase's significance is moderated by the absence of any structural flag indicating this is a discretionary conviction-driven buy versus a routine portfolio action.

Director Rodney Hochman buys 1,618 shares in first open-market purchase; stock down sharply amid cluster buying by 7 insiders in two weeks.

Director Rodney Hochman made his first open-market purchase at GE HealthCare, buying shares after prior Form 4 activity consisted entirely of stock-based compensation exercises and grants. This marks a deliberate choice to deploy personal capital into the company at a time when the stock trades well below its 52-week high, having declined notably over the past three months. The purchase occurs within a two-week window in which seven insiders at GEHC have bought shares, a pattern that suggests broad-based opportunistic buying rather than a single director's isolated decision. The company remains profitable with steady revenue growth and a reasonable valuation, providing a financial backdrop that makes the timing of multiple insider purchases noteworthy. The combination of Hochman's first-time open-market buy in a cluster context, paired with the stock's weakness, warrants tracking whether this signals an inflection point or simply reflects insiders taking advantage of a temporary dip.

Director Phoebe Watkin buys $63K in GEHC shares amid stock weakness, first open-market purchase after prior sales; 6 insiders buying within 14 days.

Director Phoebe Watkin has made her first open-market purchase in the three-year record, breaking a pattern of stock-based compensation and prior open-market sales. She acquired shares at prices well below the 52-week high, a typical window for insider activity. The purchase coincides with a notable cluster: six insiders bought GE HealthCare shares within a 14-day window, a material concentration of insider buying activity. GE HealthCare remains profitable with growing revenue and trades at a reasonable valuation multiple, providing a fundamental backdrop of operational stability. This filing is worth tracking because it marks a shift in Watkin's behavior and occurs as part of a broader wave of insider buying, though the individual transaction size is modest.

Director H. Lawrence Culp Jr. purchases $5M of GEHC shares; part of 5-insider buying cluster in 14-day window

H. Lawrence Culp Jr., a director of GE HealthCare, committed over $5 million to purchase shares, more than doubling his holdings in a single transaction. This purchase is not isolated—it's part of a coordinated buying pattern with five insiders acquiring shares within a two-week window, which suggests board-level or management alignment on the company's near-term prospects. GE HealthCare remains a profitable company with stable revenue growth and positive earnings, providing a fundamentally sound backdrop for the insider activity. When a sitting director puts substantial personal capital into the stock alongside multiple peers doing the same, it typically reflects confidence in valuation or near-term catalysts, though the cluster itself makes it difficult to isolate Culp's individual conviction from broader insider sentiment.

Director William J Stromberg purchases 1,000 GEHC shares; part of 4-insider buying cluster in two-week window

Director William J Stromberg bought a meaningful stake in GE HealthCare, increasing his holdings by 7 percent through open-market purchase. This trade is part of a broader insider buying cluster, with three other insiders purchasing shares within a two-week window—a pattern that often signals coordinated conviction at the board level rather than individual conviction alone. The company itself is profitable with growing revenue, providing a fundamentally solid backdrop for insider accumulation. When multiple board members are stepping up to buy at the same time, it typically reflects confidence that current valuations represent opportunity rather than a warning sign, making this cluster particularly noteworthy for investors evaluating the company's near-term outlook.

GE HealthCare CEO Peter Arduini buys ~4,200 shares on open market amid stock pullback from highs

Peter Arduini, the President and CEO of GE HealthCare, purchased over 4,100 shares on the open market, representing a meaningful addition to his holdings in the company he runs. This transaction stands out because it comes while the stock is trading significantly below its recent highs after a sustained pullback—typically the moment when insider conviction becomes most credible, since executives are deploying their own capital into a weakened position rather than piling in during euphoria. GE HealthCare itself remains a solidly profitable business with consistent revenue growth and reasonable valuation, suggesting the CEO is not buying a deteriorating company. Arduini's direct operational knowledge of the business combined with his willingness to increase exposure at a depressed price level sends a meaningful vote of confidence that current market sentiment has moved too far pessimistic relative to the underlying business quality.